In the UK, the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC) are currently reviewing another medicine from this Gepant group, Atogepant, for treating migraine on the NHS (at time of writing, July 2023).
Other Gepants such as Ubrogepant and Zavegepant might also be considered in the near future.
These drugs are already approved and used widely in the USA.